Search

Your search keyword '"M.A. Climent"' showing total 49 results

Search Constraints

Start Over You searched for: Author "M.A. Climent" Remove constraint Author: "M.A. Climent"
49 results on '"M.A. Climent"'

Search Results

1. Pronóstico a largo plazo de la epilepsia ausencia juvenil

2. Long term prognosis of juvenile absence epilepsy

3. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

5. 1572P The impact of COVID-19 pandemic on Spanish genitourinary (GU) cancer patients: SOGUG-COVID-19 study

6. 1572P The impact of COVID-19 pandemic on Spanish genitourinary (GU) cancer patients: SOGUG-COVID-19 study

7. 666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

8. 589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)

9. 625P TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer

10. Corrigendum to '589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)'

11. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

12. 759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy

13. 662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B

14. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

15. LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

16. 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)

17. 803TiP Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients

18. 759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy

19. PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer

20. Influence of different ways of chloride contamination on the efficiency of cathodic protection applied on structural reinforced concrete elements

21. Durability related transport properties of OPC and slag cement mortars hardened under different environmental conditions

22. Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02)

23. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

24. Impedance spectroscopy: An efficient tool to determine the non-steady-state chloride diffusion coefficient in building materials

25. Electrochemical extraction of chlorides from reinforced concrete using a conductive cement paste as the anode

26. Microstructural modifications in Portland cement concrete due to forced ionic migration tests. Study by impedance spectroscopy

27. Generalization of the possibility of eliminating the filtration step in the determination of acid-soluble chloride content in cement and concrete by potentiometric titration

28. Conservative Elective Treatment of Upper Urinary Tract Tumors: A Multivariate Analysis of Prognostic Factors For Recurrence and Progression

29. A test method for measuring chloride diffusion coefficients through nonsaturated concrete

30. Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)

31. SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials

32. Bit shape geometric considerations when sampling by dry drilling for obtaining chloride profiles in concrete

33. Analysis of acid-soluble chloride in cement, mortar, and concrete by potentiometric titration without filtration steps

34. 2635 MAJA trial: maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). Preliminary analysis of a randomized placebo controlled phase II trial. SOGUG 2011-02. EudraCT 2011-001271-39

35. Chloride Contamination of Concrete by Interaction with PVC Combustion Gases

36. Influence of using slag cement on the microstructure and durability related properties of cement grouts for micropiles

37. Proof by UV-visible modulated reflectance spectroscopy of the breakdown by carbonation of the passivating layer on iron in alkaline solution

38. 2635 MAJA trial: maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). Preliminary analysis of a randomized placebo controlled phase II trial. SOGUG 2011-02. EudraCT 2011-001271-39

39. Determination of the selectivity coefficient of a chloride ion selective electrode in alkaline media simulating the cement paste pore solution

40. Experimental confirmation of some aspects of the microstructural model of the impedance spectra of porous materials

41. Use of impedance spectroscopy to determine the displacement of water in cement paste under small loads

42. A test method for measuring chloride diffusion coefficients through partially saturated concrete. Part II: The instantaneous plane source diffusion case with chloride binding consideration

43. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment

44. 97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES)

45. Chloride-Ion activities in simplified synthetic concrete pore solutions: the effect of the accompanying Ions

46. Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

47. A phase II study of vinorelbine (VRL), cisplatin (CDDP) and 5-Fluorouracil (FU) in patients (PTS) with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

49. Measurements of Chloride Activity Coefficients in Real Portland Cement Paste Pore Solutions

Catalog

Books, media, physical & digital resources